New Horizon Health Limited announced that the Company will not be able to publish the annual results for the year ended December 31, 2023 in accordance with Rules 13.49(1) and (2) of the Listing Rules, as the Company is still in the process of addressing certain concerns raised by Deloitte Touche Tohmatsu, the auditor of the Company as mentioned in the letters to the Board and/or audit committee of the Company. The Auditor raised certain concerns in relation to the validity of certain sales transactions of ColoClear and commercial substance and business rationale of the relevant sales models; validity of certain sales transactions of Pupu Tube or UU Tube; and validity of certain selling and marketing expenses and commercial substance and business rationale of the relevant underlying marketing activities; and hence considered necessary for the Audit Committee to conduct an independent investigation. In line with the Auditor's request, the Audit Committee has engaged third-party specialists to conduct an independent investigation.

The Company is working closely with the Investigators, the Audit Committee and the Auditor and in the process of providing the necessary information and documents, as well as maintaining active dialogues with the Investigators, the Audit Committee and the Auditor to resolve all outstanding issues. However, the expected date of the publication of the 2023 Annual Results will need to be further discussed and determined, and will be announced as and when appropriate. Pursuant to Rule 13.49(1) of the Listing Rules, the Company is required to publish the 2023 Annual Results on a date not later than three months after the end of the financial year of the Company, i.e. on or before March 31, 2024.

In light of the aforementioned circumstances, there will be a delay in the Company's publication of the 2023 Annual Results, which will constitute a non-compliance of Rule 13.49(1) of the Listing Rules.